Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology
Journal of Korean Neurosurgical Society · 01.11.2026 · 69 (6) · 855-865
DOI: 10.3340/jkns.2026.0113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Korean Neurosurgical Society, erschienen am 01.11.2026. Verfasst von Kyung-Min Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Korean Brain Tumor Society, Seoul, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Advancement of molecular targeted therapies has revolutionized the treatment of several challenging and previously refractory tumors. Since the introduction of rituximab in 1997, the field of molecular targeted agents have continued to evolve. Notably, vorasidenib, a brainpenetrant dual inhibitor of mutant isocitrate dehydrogenase (IDH) 1 and 2, has recently demonstrated promising results in the 2023 INDIGO trials with improved progression-free survival and delayed need for subsequent interventions in patients with IDH-mutant low-grade gliomas. Although therapeutic options for glioma have long remained largely limited to surgery, radiation, and conventional chemotherapy despite extensive and ongoing research, the advent of vorasidenib opens a new chapter in glioma treatment. This review summarizes the key clinical studies of vorasidenib and discusses its potential role, limitations, and future directions in the evolving treatment paradigm of IDH-mutant gliomas.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Korean Brain Tumor Society, Seoul, Korea.
- Department of Neurosurgery, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
- Department of Neurosurgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
- Department of Neurosurgery, School of Medicine, Kyungpook National University, Daegu, Korea.
- Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Zitieren
APA
Kim, K. M., Byeon, Y., Lee, C., Lee, W. J., Hwang, K., Dho, Y. S., Sung, K. S., Roh, T. H., Chong, K., Park, K. S., Kang, S. H., & Kim, E. H. (2026). Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology. Journal of Korean Neurosurgical Society, 69(6), 855-865. https://doi.org/10.3340/jkns.2026.0113
Vancouver
Kim KM, Byeon Y, Lee C, Lee WJ, Hwang K, Dho YS, et al. Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology. Journal of Korean Neurosurgical Society. 2026;69(6):855-865. doi:10.3340/jkns.2026.0113
BibTeX
@article{Kim2026,
author = {Kim, Kyung-Min and Byeon, Yukyeng and Lee, Chaejin and Lee, Won-Jae and Hwang, Kihwan and Dho, Yun-Sik and Sung, Kyoung Su and Roh, Tae Hoon and Chong, Kyuha and Park, Ki-Su and Kang, Shin-Hyuk and Kim, Eui Hyun},
title = {Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology},
journal = {Journal of Korean Neurosurgical Society},
year = {2026},
volume = {69},
number = {6},
pages = {855--865},
doi = {10.3340/jkns.2026.0113}
}
EUVIMED